AbbVie Q3 FY2026: revenue $17.40 billion, adjusted EPS $3.82, guidance raised
AbbVie's third quarter of FY2026 was strong on the top line: revenue of $17.404 billion grew 10.3% and GAAP EPS more than doubled to $2.37, helped by lapping a $2.68 billion IPR&D charge from a year ago. Adjusted EPS of $3.82 essentially matched the $3.823 consensus, and full-year guidance was raised. Read the quarter through Skyrizi and Rinvoq, not the GAAP jump.
1 · Expected vs. Actual
Free preview belowGAAP EPS of $2.37 was more than double last year's $0.10, but most of that swing is a comparison effect: the year-ago quarter carried $2.68 billion of acquired IPR&D and milestones expense versus $216 million this quarter. Adjusted EPS of $3.82 against $1.86 is still a doubling, and it landed within a rounding error of the $3.823 consensus. Both figures absorbed a $0.11 per-share hit from acquired IPR&D booked in the quarter.
Revenue of $17.404 billion rose 10.3% from $15.776 billion a year earlier, and the growth came almost entirely from immunology and neuroscience. Skyrizi at $5.776 billion (+22.7%) and Rinvoq at $2.706 billion (+23.9%) together produced $8.482 billion, nearly half of total revenue. Humira fell 31.2% to $683 million, a hole the two newer drugs more than covered.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-04
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.